8-KRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Aug 22, 2011)

Filed August 22, 2011For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 22, 2011, to announce the presentation of data from its Phase 3 COPERNICUS Study. This study evaluated VEGF Trap-Eye for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). The presentation, scheduled for the American Society of Retina Specialists meeting, marks a significant step in the clinical development of this potential therapy. Investors should focus on the 1-year results from this pivotal Phase 3 trial. The data presented are expected to provide crucial insights into the safety, efficacy, and tolerability of repeated intravitreal administration of VEGF Trap-Eye. Positive results from this study would be a strong indicator for the potential regulatory approval and commercial success of VEGF Trap-Eye, a key pipeline asset for Regeneron.

Key Highlights

  • 1Regeneron presented Phase 3 COPERNICUS Study data for VEGF Trap-Eye on August 22, 2011.
  • 2The study focuses on treating macular edema secondary to central retinal vein occlusion (CRVO).
  • 3The data presented are 1-year results, providing long-term efficacy and safety insights.
  • 4Presentation took place at the American Society of Retina Specialists meeting.
  • 5Exhibit 99.1 contains the slides presented, offering detailed study results.
  • 6VEGF Trap-Eye is a key investigational drug for Regeneron's pipeline in ophthalmology.

Frequently Asked Questions

The COPERNICUS Study is a Phase 3 clinical trial evaluating VEGF Trap-Eye, a potentially important drug for Regeneron. Positive results from this pivotal study are crucial for regulatory approval and commercialization, particularly for treating macular edema secondary to central retinal vein occlusion (CRVO).

VEGF Trap-Eye is being investigated for the treatment of macular edema secondary to central retinal vein occlusion (CRVO), a serious condition affecting vision.

The detailed results are available in the presentation slides furnished as Exhibit 99.1 to this Form 8-K filing.

The data presented are 1-year results, offering insights into the longer-term safety and efficacy of repeated intravitreal administration of VEGF Trap-Eye.